Intra Cellular Therapies | Bénéfice Avant Impôts



Pre Tax Profit Changement Date
Acadia Pharmaceuticals USD 161.08M 122.28M 2024-12
ALKERMES USD 443.75M 333.52M 2024-12
Biogen USD 572.2M 118.5M 2024-12
Bristol-Myers Squibb USD 4.26B 226M 2024-12
Cytokinetics USD -150020000 10.52M 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
Halozyme Therapeutics USD 557.13M 359.8M 2024-12
Intra Cellular Therapies USD -17202000 8.75M 2024-12
J&J USD 5.42B 1.86B 2024-12
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Novartis USD 4.66B 269M 2024-12
Prothena USD -59501000 335K 2024-12
RedHill Biopharma USD -1540000 12M 2024-06
Supernus Pharmaceuticals USD 26.38M 45.36M 2024-12
United Therapeutics USD 396.5M 7.9M 2024-12



Intra Cellular Therapies Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.